ARA-290
$Human clinical research for neuropathy/inflammation; Not broadly approved
ARA-290, also called cibinetide, is engineered from erythropoietin biology but is designed not to increase red blood cell production. Its intended target is the innate repair receptor, which is upregulated during tissue stress and injury.
This is one of the more clinically grounded experimental entries because small human studies exist in neuropathic and inflammatory conditions. Still, the evidence is condition-specific. Improvement in small fiber neuropathy does not automatically prove benefit for every inflammatory or “recovery” use case.
The key distinction is EPO-like origin without the classic EPO red-blood-cell effect. Separate plasma half-life from biological signaling duration: the peptide may clear quickly while receptor-triggered repair signaling lasts longer.
Classification details
- ARA-290 is a synthetic 11-amino acid peptide derived from the structure of Erythropoietin (EPO).
- However, it is specifically designed to be “non-erythropoietic,” meaning it does not stimulate red blood cell production.
- Instead, it is a selective agonist for the Innate Repair Receptor (IRR).
- It is classified as a powerful anti-inflammatory and neuroprotective agent.
- ARA-290, also called cibinetide in development contexts, is an EPO-derived peptide designed to activate tissue-protective signaling without classical erythropoietic stimulation.
ARA-290 targets the body’s primary “distress” signaling system to shut down chronic inflammation and initiate repair:
- Selective IRR Binding: In the presence of tissue injury or metabolic stress, the body expresses the Innate Repair Receptor (a complex of the EPO receptor and the beta-common receptor). ARA-290 binds to this specific heteromer.
- Inflammation Suppression: Once bound, it inhibits the production of pro-inflammatory cytokines (like TNF-alpha and IL-6) and prevents the activation of the “inflammasome.” Small-fiber neuropathy research: ARA-290/cibinetide has been studied in sarcoidosis-associated small-fiber neuropathy and painful diabetic neuropathy, including corneal and skin small-fiber endpoints.
- This supports an investigational nerve-repair rationale, not a guaranteed or unique ability to repair small-fiber neuropathy.
- Apoptosis Prevention: It protects cells from “programmed cell death” triggered by ischemia (lack of oxygen) or oxidative stress.
- The key mechanism frame is innate repair receptor/tissue-protective signaling, including anti-inflammatory and neuroprotective pathways. It is not a general nerve-regeneration guarantee.